Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. HUTCHMED (China) Limited
  6. News
  7. Summary
    HCM   KYG4672N1198

HUTCHMED (CHINA) LIMITED

(HCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about HUTCHMED (CHINA) LIMITED
01/13Chinese Regulators Grant Breakthrough Therapy Designation to Hutchmed's Immune Thromboc..
MT
01/12HUTCHMED Secures Breakthrough Therapy Designation in China for Primary Immune Thrombocy..
MT
01/12HUTCHMED CHINA : Receives Break­through Therapy Designation in China for HMPL-523 for Trea..
PU
01/12HUTCHMED Limited Receives Breakthrough Therapy Designation in China for HMPL-523 for Tr..
CI
01/10HUTCHMED CHINA : Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previo..
PU
01/10Hutchmed Launches Phase 1 Trial of HMPL-76 in Patients with Previously Treated B-Cell N..
MT
01/10Hutchmed Starts Early-Stage Trial of Blood Cancer Treatment
MT
01/10HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously ..
CI
01/09Hutchmed China Starts Phase 1 Trial of Non-Hodgkin Lymphoma Treatment in China
MT
01/09HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously ..
AQ
01/03HUTCHMED CHINA : Blocklisting Six Monthly Return - Form 6-K
PU
2021Certain American Depositary Shares of HUTCHMED Limited are subject to a Lock-Up Agreeme..
CI
2021Certain Ordinary Shares of HUTCHMED Limited are subject to a Lock-Up Agreement Ending o..
CI
2021HUTCHMED CHINA : Included in FTSE Russell Indexes - Form 6-K
PU
2021Hutchmed Added to FTSE Russell Indexes
MT
More most relevant news
All news about HUTCHMED (CHINA) LIMITED
01/13Chinese Regulators Grant Breakthrough Therapy Designation to Hutchmed's Immune Thromboc..
MT
01/12HUTCHMED Secures Breakthrough Therapy Designation in China for Primary Immune Thrombocy..
MT
01/12HUTCHMED CHINA : Receives Break­through Therapy Designation in China for HMPL-523 for Trea..
PU
01/12HUTCHMED Limited Receives Breakthrough Therapy Designation in China for HMPL-523 for Tr..
CI
01/10HUTCHMED CHINA : Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previo..
PU
01/10Hutchmed Launches Phase 1 Trial of HMPL-76 in Patients with Previously Treated B-Cell N..
MT
01/10Hutchmed Starts Early-Stage Trial of Blood Cancer Treatment
MT
01/10HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously ..
CI
01/09Hutchmed China Starts Phase 1 Trial of Non-Hodgkin Lymphoma Treatment in China
MT
01/09HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously ..
AQ
More news
News in other languages on HUTCHMED (CHINA) LIMITED
01/12HUTCHMED (China) Limited reçoit la désignation de thérapie innovante en Chine pour le H..
01/10Hutchmed lance un essai précoce d'un traitement contre le cancer du sang
01/10HUTCHMED lance une étude de phase I sur l'inhibiteur de BTK HMPL-760 chez des patients ..
2021Hutchmed achève le recrutement de patients pour un essai clinique sur le cancer colorec..
2021Hutchmed achève le recrutement des patients pour l'étude mondiale de phase 3 d'un médic..
2021Deux thérapies anticancéreuses de Hutchmed figurent sur la liste des médicaments rembou..
2021Les actions du secteur de la santé sont mitigées mercredi avant le marché
2021Hutchmed et AstraZeneca lancent un essai de phase 3 sur le cancer du poumon en Chine
2021AstraZeneca et Hutchmed lancent un essai de phase avancée d'un traitement combiné contr..
2021Hutchmed et AstraZeneca lancent un essai de phase 3 sur une combinaison de médicaments ..
More news
Analyst Recommendations on HUTCHMED (CHINA) LIMITED
2021HUTCHMED CHINA : Goldman Sachs Downgrades Hutchison China MediTech to Neutral From Buy
MT
2021HUTCHMED CHINA : Jefferies Initiates Hutchison China MediTech at Buy Rating With $52 Price..
MT
More recommendations
Press releases
01/12HUTCHMED CHINA : Receives Break­through Therapy Designation in China for HMPL-523 for Trea..
PU
01/10HUTCHMED CHINA : Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previo..
PU
01/09HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously ..
AQ
01/03HUTCHMED CHINA : Blocklisting Six Monthly Return - Form 6-K
PU
2021HUTCHMED CHINA : Included in FTSE Russell Indexes - Form 6-K
PU
More press releases
Upcoming event on HUTCHMED (CHINA) LIMITED